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Background: Microarray technology may offer a new opportunity to gain insight into disease-specific global
protein expression profiles. The present study was performed to apply a serum antibody microarray to screen for
differentially regulated cytokines in Parkinson's disease (PD), multiple system atrophy (MSA), progressive
supranuclear palsy (PSP) and corticobasal syndrome (CBS).
Results: Serum samples were obtained from patients with clinical diagnoses of PD (n = 117), MSA (n = 31) and PSP/
CBS (n = 38) and 99 controls. Cytokine profiles of sera from patients and controls were analyzed with a
semiquantitative human antibody array for 174 cytokines and the expression of 12 cytokines was found to be
significantly altered. In a next step, results from the microarray experiment were individually validated by different
immunoassays. Immunoassay validation confirmed a significant increase of median PDGF-BB levels in patients with
PSP/CBS, MSA and PD and a decrease of median prolactin levels in PD. However, neither PDGF-BB nor prolactin
were specific biomarkers to discriminate PSP/CBS, MSA, PD and controls.
Conclusions: In our unbiased cytokine array based screening approach and validation by a different immunoassay
only two of 174 cytokines were significantly altered between patients and controls.Background
In addition to the clinical assessment, biomarkers could
provide important information not only for the diagnosis
of Parkinson’s disease (PD), but also to differentiate idio-
pathic PD from different entities of atypical Parkinsonian
disorders (APDs) as well as to identify persons being at
risk of developing the disease. Furthermore, biomarkers
could be a helpful tool to evaluate the progression and
the severity of PD.
Although several specific biomarker assays in bio-
logical fluids such as cerebrospinal fluid (CSF), plasma,
urine and serum of patients with neurodegenerative dis-
eases have been under investigation, the vast majority of
them have produced disappointing results [1,2]. Recent* Correspondence: Markus.Reindl@i-med.ac.at
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distribution, and reproduction in any mediumresearch focused on the quantification of alpha-
synuclein and DJ-1, two proteins critically involved in
PD pathogenesis, in CSF with more promising results
[3-5]. A comparable problem is seen in Alzheimer’s dis-
ease (AD), which is also difficult to diagnose in its earli-
est stages and CSF biomarkers have been established for
the diagnosis of AD [6]. However, peripheral blood is
much easier to obtain and not all patients are willing to
undergo lumbar puncture. Therefore, it was a major
breakthrough when two recent studies described a
cytokine-array based investigation of secreted signaling
proteins in the peripheral blood that distinguished sam-
ples from patients with AD and control subjects [7,8].
Subsequent studies, however, showed controversial
results [9,10]. Using a similar technique as a screening
tool, another recent study found low epidermal growth
factor levels in cognitively impaired PD patients [11]. In-
creasing evidence has linked chronic central and periph-
eral immune and inflammatory mechanisms to PDntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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to PD could cause characteristic changes in the concen-
trations of signaling proteins in the blood. Indeed differ-
ent cytokines (brain derived neurotrophic factor, tumor
necrosis factor alpha and interleukin 6) have been
reported to be significantly altered in the sera of PD
patients [13-15]. The present study was aimed to apply a
screening approach using a cytokine-array with 174
secreted signaling proteins to screen serum samples
from patients with PD and from patients with APDs
such as progressive supranuclear palsy (PSP), corticoba-
sal syndrome (CBS) and multisystem atrophy (MSA) as
well as controls for deregulation of serum proteins. In a
second step results from the microarray screening ex-
periment were evaluated by different immunoassays.Results
Human cytokine antibody array experiments
We have applied a screening approach with human cyto-
kine antibody arrays using pooled serum samples from
patients with PSP/CBS, MSA, PD and age and sex-
matched controls (CTRL) to identify putative serum bio-
markers for these diseases (Table 1A). In order to
exclude an effect of age-related non-neurological dis-
eases on serum cytokine levels we have not only
included 63 age and sex matched healthy blood donors
(HC), but also 36 patients with internal diseases (INC)Table 1 Demographic and clinical data of patients and
controls
A. Screening cohort analyzed in cytokine microarray experiment
PSP/CBS MSA PD CTRL p-value
Number 10 10 20 30
Female, n(%) 6(60) 6(60) 12(60) 18(60) nsb
Age, ya 68(54–75) 66(54–75) 67(52–81) 65(56–80) nsc
Duration, ya 4(1–8) 5(1–9) 6(1–37) nsc
Hoehn&Yahra 3(2–5) 4(2–5) 2(1–4) <0.001c
Dementia, n(%) 3(30) 2(20) 2(10) nsb
Treatment, n(%) 9(90) 5(50) 18(90) ns
B. Replication cohort
PSP/CBS MSA PD CTRL p-value
Number 28 21 97 69
Female, n(%) 14(50) 14(67) 32(33) 29(42) 0.03b
Age, ya 74(57–84) 63(46–78) 66(41–85) 63(42–93) <0.001c
Duration, ya 3(1–11) 3(1–6) 4(0–27) nsc
Hoehn&Yahra 4(2–5) 4(0–5) 2(0–5) <0.001c
Dementia, n(%) 14(52) 0(0) 10(11) <0.001b
Treatment, n(%) 19(68) 15(71) 63(65) nsb
y = years, ns = not statistically significant, treatment = patients treated with
levodopa and/or dopamine agonists and/or monoamine oxidase inhibitors
a data are shown as median (range), p-value: groups were compared using
b Chi-Square test and c Kruskal-Wallis test.in our control group. Figure 1 shows a heatmap of the
microarrays for the four groups of patients and controls.
Using significance of microarray (SAM) analysis, we
discovered 12 significant results at a false discovery rate
(FDR) cut-off of <0.001%. Figure 1B and Additional file 1
summarize the differentially regulated cytokines
found in our arrays using SAM analysis. The significantly
differentially expressed cytokines were growth-regulated
alpha protein (GRO = CXCL1), intercellular adhesion
molecule 1 (ICAM-1 = ICAM1), interleukin-2 receptor
alpha chain (IL-2R alpha = IL2RA), interleukin-6 receptor
subunit alpha (IL-6 R = IL6R), leptin (LEP), C-C motif
chemokine 13 (MCP-4 = CCL13), neutrophil-activating
peptide 2 (NAP-2 = PPBP), platelet-derived growth factor
subunit B (PDGF-BB = PDGFB), prolactin (PRL), C-C
motif chemokine 5 (RANTES = CCL5), metalloprotei-
nase inhibitor 2 (TIMP-2 = TIMP2) and tumor ne-
crosis factor related apoptosis inducing ligand
receptor 3 (TRAIL R3 = TNFRSF10C). A post-hoc
analysis revealed no statistically significant differ-
ences for these cytokines between INC and HC
within the control group.
The DAVID v6.7 tool was used for functional annota-
tion clustering of the 12 identified cytokines. As can be
seen from Table 2, gene functional classification clus-
tered cytokines into 10 groups with highest stringency
with enrichment scores ranging from 1.63 to 7.28. The
highest enrichment scores were seen for cytokines asso-
ciated with immune responses, chemotaxis and cell
migration, whereas no association with neuronal or glial
function was found.
Validation of microarray data by ELISA and flow-cytomix
assays
Since the cytokine microarray analysis was performed
using pooled samples from the screening cohort, we
decided to validate the results of the microarray analysis
by ELISA (MCP-4, prolactin, RANTES and IL-2RA) and
by Flow-Cytomix assays (ICAM-1, leptin and PDGF-BB)
applied on individual samples for seven of the 12 cyto-
kines. These seven cytokines were selected based on the
results from the microarray experiments, the availability
of commercial available test kits and the amount of
serum left. We used the same serum samples as shown
in Table 1A and the results of these validation experi-
ments are shown in Table 3 and Figure 2. However, only
two (PDGF-BB and prolactin) of the seven cytokines
were significantly different amongst patients (PSP/CBS,
MSA and PD) and controls, whereas we could not con-
firm the cytokine microarray results for ICAM-1, IL-2RA,
leptin, MCP-4 and RANTES (Figure 2). A separate analysis
of both control groups, HC and INC, did not change the
results.
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Figure 1 Identification of serum biomarkers for the discrimination of movement disorders by antibody arrays in the screening cohort.
(A) Representative picture of Raybiotech human cytokine antibody array showing the reactivity of pooled serum samples (10 PSP/CBS, 10 MSA, 20
PD and 30 controls) to arrays G series 2000 6, 7 and 8 (174 cytokines). Each protein was measured in duplicates. Signals were scanned with a
GenePix 4000B scanner. Blue boxes: positive controls (upper left corner, high intense spots). Red box, negative controls (upper left and lower right
corner, no spots). Purple boxes, internal controls IC1, IC and IC3 (lower right corner, spots with three different intensities). White and green
colored boxes indicate the location of the detection of two proteins that were significantly different in both the microarray and validation
experiment (white = PDGF-BB and green = prolactin). (B) Normalized array data of the 174 cytokines were analyzed by SAM to detect differences
in their concentrations between pooled serum samples (PSP/CBS, one pool of 10 samples with three replicates; MSA, one pool of 10 samples
with three replicates each; PD, two pools of 10 samples with two replicates each; and controls, three pools of 10 samples with two replicates
each). The relative concentrations of the 12 cytokines that obtained a significant score (q-value <0.001%) are shown in a “heatmap”. Low
concentrations are shown in blue, median concentrations in black and high concentrations in yellow.
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Table 2 Functional annotation clustering of identified cytokines using the DAVID database
DAVID annotation cluster Enrichment score, p-value Associated Cytokines
1. Immune response, immunity and defense 7.28, p < 10-6 GRO, ICAM-1, MCP-4, IL-2RA, NAP-2, IL-6R, RANTES
2. Chemotaxis, taxis, locomotory behavior 6.64, p < 10-8 GRO, MCP-4, NAP-2, PDGF-BB, IL-6R, RANTES
3. Chemokine 4.23, p < 10-6 GRO, MCP-4, NAP-2, RANTES
4. Cell migration, leukocyte migration, cell motility 3.13, p < 10-5 ICAM-1, PDGF-BB, IL-6R, RANTES
5. Cell chemotaxis, response to steroid hormone stimulus 2.70, p < 10-4 PDGF-BB, IL-6R, RANTES
6. Regulation of cell migration, motion and locomotion 2.31, p < 0.01 ICAM-1, PDGF-BB, IL-6R
7. Response to hormone stimulus 2.24, p < 0.01 leptin, PDGF-BB, IL-6R, RANTES
8. Positive regulation of signal transduction 1.77, p < 0.05 leptin, IL6-R, prolactin
9. Diabetes type 2, metabolic disease, reproduction 1.63, p < 0.05 leptin, ICAM-1, IL-6R, RANTES
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and prolactin to a replication cohort of patients and con-
trols (Table 1B) and to all patients and controls. Figures 2
and 3 demonstrate that these two cytokines were signifi-
cantly different among the four groups in the screening
and replication cohorts and in the combined data.
PDGF-BB was significantly increased in PSP/CBS, MSA
and PD and prolactin was significantly decreased in PD
(Figure 3, Table 4). From Table 4 it is also evident that
PDGF-BB levels were mainly influenced by the clinical
diagnosis, whereas prolactin levels were more strongly
influenced by antiparkinson treatment (p = 7x10-13) than
by clinical diagnosis (p = 7x10-7).
This was also seen in a multivariate analysis including
prolactin serum levels as dependent variable and diagno-
ses (PSP/CBS, MSA, PD, controls), sex, age and dopa-
minergic antiparkinsonian treatment as independent
variables revealed that serum prolactin levels were influ-
enced only by antiparkinsonian treatment (p < 0.001),Table 3 Validation of the serum cytokine array experiment in
Cytokine Method PSP/CBS MSA
ICAM-1 Array 0.98 ± 0.25 0.47 ± 0
(ICAM1) FCM 1.25 ± 0.85 0.75 ± 0
IL-2 Ra Array 2.14 ± 0.47 1.87 ± 0
(IL2RA) ELISA 1.44 ± 0.76 1.24 ± 0
Leptin Array 1.93 ± 0.11 1.13 ± 0
(LEP) FCM 2.95 ± 4.89 1.42 ± 1
MCP-4 Array 7.18 ± 0.85 2.16 ± 1
(CCL13) ELISA 1.15 ± 0.32 0.91 ± 0
PDGF-BB Array 1.87 ± 0.50 1.34 ± 0
(PDGFB) FCM 1.42 ± 0.30 1.32 ± 0
Prolactin Array 4.17 ± 1.74 1.03 ± 0
(PRL) ELISA 3.06 ± 4.15 1.39 ± 1
RANTES Array 1.46 ± 0.29 1.32 ± 0
(CCL5) ELISA 1.13 ± 0.59 0.83 ±0
Cytokine microarray data were validated by ELISA (MCP-4, prolactin, RANTES and IL
samples. All data are shown as means with standard deviations of the ratio to the m
FCM = Flow-Cytomix, ELISA = enzyme-linked immunosorbent assay, ns = statisticall
P-value: groups were compared using a SAM analysis and b Kruskal-Wallis test.but not by diagnoses, sex and age (p = ns). Further-
more from Additional file 2 it is evident that in the
subgroup of early untreated patients median prolactin
levels did not differ between the various patient
groups [PSP/CBS (n = 10; 3.3 ng/ml; range 1.1-5.8),
MSA (n = 11; median 2.9 ng/ml; 0.2-19.3), PD (n = 37;
median 3.6 ng/ml; 0.2-21.5) and controls (n = 99; median
3.7 ng/ml; 0.5-37.5)].
In contrast, multivariate analysis revealed that serum
PDGF-BB levels were influenced by the diagnoses only
(p < 0.001), but not by antiparkinsonian treatment, sex
and age (p = ns). Also in our early untreated patients
PDGF-BB serum levels were significantly different
(p < 0.001) between patient groups (Additional file 2).
Median PDGF-BB serum levels were 8.6 ng/ml (range
5.7-12.0) in patients with PSP/CBS (n = 10), 8.4 ng/ml
(4.4-10.1) in patients with MSA (n = 11), 7.9 ng/ml
(3.0-12.7) in patients with PD (n = 37) and 5.9 ng/ml
(2.0-10.8) in controls (n = 99).the initial screening cohort
PD Controls p-value
.09 0.62 ± 0.15 1.00 ± 0.28 <0.05a
.29 0.86 ± 0.43 1.00 ± 0.73 nsb
.10 1.24 ± 0.06 1.00 ± 0.14 <0.05a
.61 1.15 ± 0.55 1.00 ± 0.29 nsb
.23 1.91 ± 0.46 1.00 ± 0.11 <0.05a
.15 1.86 ± 1.88 1.00 ± 0.89 nsb
.39 1.71 ± 0.80 1.00 ± 0.76 <0.05a
.37 1.02 ± 0.32 1.00 ± 0.42 nsb
.18 1.34 ± 0.22 1.00 ± 0.44 <0.05a
.39 1.11 ± 0.28 1.00 ± 0.33 <0.05b
.15 0.99 ± 0.08 1.00 ± 0.19 <0.05a
.34 0.71 ± 1.12 1.00 ± 0.50 <0.05b
.11 1.20 ± 0.25 1.00 ± 0.20 <0.05a
.49 0.94 ± 0.32 1.00 ± 0.51 nsb
-2RA) or by Flow-Cytomix assays (ICAM-1, Leptin and PDGF-BB) in individual






































































































































































































































































Figure 2 Validation of seven differentially expressed cytokines in patients with PSP/CBS, MSA and controls in the screening cohort.
Individual data points are shown as circles or triangles and horizontal bars indicate medians. In addition data are shown as box plots with
medians indicated as horizontal bars with boxes. Groups were compared using the Kruskal-Wallis test and Dunn’s multiple comparison post-hoc
test and overall p-values for comparison of PSP/CBS, MSA and combined controls or for comparison of PSP/CBS, MSA, HC and INC are shown in
each figure. Ns = statistically not significant.

















































































































































































Figure 3 Differential expression of PDGF-BB and prolactin in patients with PSP/CBS, MSA and controls in the screening and replication
cohorts. Individual data points are shown as circles and horizontal bars indicate medians. In addition data are shown as box plot with medians
indicated as horizontal bars with boxes. Groups were compared using the Kruskal-Wallis test and Dunn’s multiple comparison post-hoc test and
overall p-values are shown in each figure. * Significant differences to the control group, # significant differences to PD patients.
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To our knowledge this is the first study using an un-
biased cytokine microarray analysis approach to identify
potential serum biomarkers for the discrimination of
neurodegenerative parkinsonian disorders. In our study
the primary screen using cytokine microarray analysis
on pooled samples yielded 12 cytokines differentially
regulated in PSP/CBS, MSA, PD and controls (GRO,
ICAM-1, IL-2 R-alpha, IL-6 R, leptin, MCP-4, NAP-2,
PDGF-BB, prolactin, RANTES, TIMP-2 and TRAIL R3).
Functional annotation clustering revealed that these
cytokines are associated with immune responses, chemo-
taxis and cell migration, whereas no association with
neuronal or glial function was found. These resultssuggest that it is rather unlikely that the identified cyto-
kines are markers reflecting specific pathophysiological
processes for neurodegenerative parkinsonism.
By using a second independent, analytic method
(ELISA or bead-based immunoassays), we have tried to
confirm the results derived from the microarray analysis
in the same samples for seven of these 12 cytokines
(ICAM-1, IL-2 RA, leptin, MCP-4, PDGF-BB, prolactin
and RANTES). However, only two (PDGF-BB and pro-
lactin) of the seven cytokines were significantly different
amongst patient groups (PSP/CBS, MSA and PD) and
controls using both methods. In a second step we were
able to confirm these results in a different cohort con-
taining larger number of patients and controls. The
Table 4 Association of serum PDGF-BB and Prolactin
levels (in ng/ml) with clinical parameters
PDGF-BB (ng/ml) Prolactin (ng/ml)
Disease:
PSP/CBS (n = 38) a 8.7 (2.7-12.6) 3.4 (0.3-41.2)
MSA (n = 31) a 8.4 (2.9-11.6) 3.3 (0.1-74.1)
PD (n = 117) a 6.9 (3.0-12.7) 2.3 (0.0-35.1)
Controls (n = 99) a 5.9 (2.0-10.8) 3.7 (0.5-37.5)
p = 4x10-7 b p = 3x10-7 b
Females (n = 132) a 6.7 (2.4-12.7) 3.1 (0.0-74.1)
Males (n = 153) a 6.8 (2.0-12.0) 3.3 (0.0-37.4)
p = ns c p = ns c
Age, y R = 0.006 R = −0.040
p = ns d p = ns d
Duration, y R = −0.183 R = −0.226
p = ns d p = ns d
Hoehn&Yahr R = 0.105 R = 0.217
p = ns e p = 0.02 e
Dementia (n = 31) a 8.3 (4.2-12.6) 3.1 (0.0-35.1)
No Dementia (n = 148) a 7.1 (2.6-12.7) 2.7 (0.0-74.1)
p = 0.038 c p = ns c
Parkinson treatment:
None (n = 48) a 6.5 (2.0-12.7) 3.6 (0.2-37.5)
LD (n = 48) a 7.4 (2.7-12.6) 4.0 (0.0-74.1)
DA (n = 8) a 6.6 (3.7-8.6) 0.0 (0.0-3.1)
MAO-B Inh. (n = 8) a 8.1 (5.5-11.4) 2.8 (1.7-4.7)
LD + DA (n = 48) a 6.1 (2.9-11.4) 0.2 (0.0-33.2)
LD +MAO-B Inh. (n = 12) a 10.3 (5.0-11.7) 9.4 (0.3-41.2)
LD + DA +MAO-B Inh. (n = 7) a 6.9 (5.6-10.4) 0.3 (0.0-19.9)
p = 0.002 b p = 7x10-13 b
a Data are shown as median (range). Associations were statistically analyzed by
b Kruskal Wallis test, c Mann–Whitney U tests, d linear regressions and e
Spearman’s correlations. P-values were corrected for 7 comparisons by
Bonferroni’s correction for multiple comparisons.
Abbreviations: ns = not statistically significant, R = correlation coefficient,
LD = patients treated with levodopa, DA = patients treated with dopmaine
agonists, MAO-B Inh. = patients treated with monoamine oxidase inhibitors.
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replication by a different method likely reflects differ-
ences in the sensitivity and specificity of the used anti-
bodies and appears to be consistent with the frequent
irreproducibility of many serum biomarker studies of
neurodegenerative diseases. For instance the results of a
recent study describing a cytokine-array based investiga-
tion of protein-panels enabling to distinguish patients
with AD from HC [7] could not be reproduced in two
subsequent studies [9,10]. Beside this methodological
concern, our results suggest that the serum prolactin
levels are influenced by dopaminergic antiparkinsonian
treatment, but not the patient group; dopaminergic anti-
parkinsonian treatment remained the only significant
variable on prolactin levels in a multivariate analysis andpatients with no such treatment had similar serum pro-
lactin levels to controls. This is in line with studies indi-
cating a crucial role for dopamine as an inhibitor of
prolactin production as well as with studies suggesting
that untreated PD patients have normal prolactin re-
lease, whereas pharmacologic stimulation of dopamine
D2-receptors with dopaminergic antiparkinsonian treat-
ment leads to decreased serum prolactin levels [16-18],
corroborating the reliability of our cytokine-array
screening approach.
Serum PDGF-BB levels were significantly increased in
the patient groups compared to the controls with the
highest levels found in PSP/CBS. PDGF-BB, a member
of the platelet-derived growth factor family, is a homodi-
mer encoded by the PDGFB gene [19]. PDGF was ori-
ginally discovered in serum and identified as a major
mitogenic factor for connective tissue cells as well as
some epithelial and endothelial cells. In addition, PDGF
is chemotactic for fibroblasts, smooth muscle cells, neu-
trophils and mononuclear cells. However, PDGF also
appears to be ubiquitous in neurons throughout the
CNS, where it is suggested to play an important role in
neural development, function and neuron survival as
well as in mediation of glial cell proliferation and differ-
entiation [19]. Experimental studies from the 1990s
demonstrated that PDGF-BB acts as a trophic factor for
rat and human mesencephalic dopaminergic neurons
promoting gene expression, survival and neurite out-
growth in culture [20,21]. In the 6-OHDA rat model,
PDGF could counteract the 6-OHDA-induced degener-
ation of mesencephalic DA neurons when administered
prior to the insult [22]. In the same in vivo model,
PDGF-BB as well as BDNF administration post insult
was capable of increasing the numbers of newly formed
cells in the striatum and substantia nigra [23]. To the
best of our knowledge there are no studies reporting on
PDGF concentrations in brain tissue or in the CSF from
parkinsonian patients. In peripheral blood, levels of
PDGF-BB have been analyzed in AD, but the results of
studies were controversial [7,9,10,24]. Interestingly, the
most recent of these studies also included 11 demented
PD patients and, in line with our results, they found an
increase in PDGF-BB levels in their plasma [10].
In our cohort of patients with neurodegenerative
parkinsonian syndromes, there was no association of
PDGF-BB levels with the disease duration or the
Hoehn and Yahr score. Also in the subgroups of early
untreated patients PDGF was elevated to the same ex-
tent as in the whole groups. Thus, it is tempting to
speculate that the increased serum PDGF-BB levels
might reflect early compensatory mechanisms as a re-
sponse to neurodegeneration. This would appear con-
sistent with increasing evidence that immunological
and inflammatory processes including microglial over-
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cytokines could be a key player in PD pathogenesis
[12]. PDGF-BB elevations could therefore represent an
important factor in central and peripheral communica-
tion between neurons, glial cells and peripheral im-
mune cells. Besides the expression in neurons and
Schwann cells, PDGF-BB is also synthesized by vascu-
lar endothelial cells, macrophages, fibroblasts and
megakaryocytes [25]. Since PDGF-BB has several im-
portant functions in the peripheral circulation such as
mitogenic and chemotactic effects on mesenchymal
stem cells [26-29], it is more likely that the increased
serum PDGF-BB levels observed in our study might
reflect a response to pathological changes in the per-
iphery. This could explain why PDGF-BB was also de-
tectable in our control sera to a marked extent, which
accounts for the suboptimal differentiation of neurode-
generative Parkinsonian syndromes from controls. Our
study has some limitations: it was performed in patients
with a clinical diagnosis of neurodegenerative parkinson-
ian syndromes without pathological confirmation. Hence,
misdiagnosis in some patients, especially in the early
disease stages, cannot be excluded. Also, some of the
included PSP patients suffered from the most reliably
identifiable classic picture of PSP (i.e. Richardson’s syn-
drome), whereas the true diagnostic dilemma lies with
atypical presentations like PSP-parkinsonism [30].
Given the pathological heterogeneity of a ‘corticobasal
syndrome’ [31], most commonly including CBS and
other neurodegenerative causes such as PSP with both
diseases sharing the same tauopathy and due to the
limited number of CBS patients (n = 8) included into
the present study, these two groups were gathered to-
gether. However, in all validation experiments CBS and
PSP patients were analyzed separately and we found
no differences between these groups. Furthermore, we
only analyzed seven out of twelve deregulated cytokines
in the initial cytokine array, depending on the availabil-
ity of commercial available test kits. Therefore, the de-
regulation of five proteins significantly altered in the
initial screening was not further validated (GRO, IL-6
R = IL6R, NAP-2, TIMP-2, TRAIL R3). The cross sec-
tional design of our study did not allow for a direct
correlation of PDGF-BB levels and disease progression.
Therefore a longitudinal study is now needed to ad-
dress this important question. Finally, our control
group included not only healthy controls, but also
patients with internal diseases. We think that this is not a
limitation but rather a strength since these controls
could avoid confounding effects of internal diseases
related to aging in patients with neurodegenerative
diseases. However, a post-hoc analysis revealed no differ-
ences between INC and HC for the cytokines analyzed in
this study.Conclusions
In conclusion we have for the first time used a serum
cytokine microarray approach to identify factors deregu-
lated in PSP/CBS, MSA and PD. Only two of 174 cyto-
kines analyzed (PDGF-BB and prolactin) were significantly
altered between patients and controls, but none of them
seem to be useful biomarkers for these diseases.
Methods
Ethics statement
The present study was approved by the ethical commit-
tee of Innsbruck Medical University (study no.:
AM1979d) and all patients gave written informed con-
sent to the study protocol.
Patients and serum samples
Patients with PSP or CBS (n = 38), PD (n = 117) and
MSA (n = 31) were seen at the Movement Disorder out-
patient clinic at the Clinical Department of Neurology at
Innsbruck Medical University. Clinical diagnosis of these
disorders had been made according to established cri-
teria by movement disorder specialists (K.S., C.S., G.K.
W., W.P.) and most patients were under regular follow
up for more than 5 years at our institution. Due to the
limited number of CBS patients (n = 8) included into the
present study and due to the clinical and pathological
overlap between PSP and CBS [31], these two groups
were analysed together. Dementia was clinically diag-
nosed using DSM-IV criteria.
Serum samples of 63 age and gender matched healthy
blood donors (HC) obtained from the blood transfusion
center of Innsbruck University Hospital and 36 patients
with internal diseases (INC; two or more of the follow-
ing: chronic kidney disease, coronary heart disease,
hypertonus, type 2 diabetes, chronic obstructive pul-
monary disease, liver cirrhosis, autoimmune disease, in-
fectious diseases and malignancy) without neurological
impairment recruited from the Department of Internal
Medicine were used as controls. The latter control group
was chosen to control for a confounding effect of in-
ternal diseases related to disability and/or aging.
All serum samples were collected prospectively from
2007 to 2010, after lunch (1.00 pm to 4.00 pm during
outpatient clinic and ward rounds) respectively, centri-
fuged and stored at −80°C within one hour after blood
withdrawal. The clinical and demographic data of all
patients are shown in Table 1. Before analysis sample
were aliquoted and stored at −80°C (one freeze-thaw
cycle).
Human cytokine antibody array and immunoassays
Human sera of patients and control groups were pooled
(Table 1) and their cytokine profiles were analyzed with
a semiquantitative human cytokine antibody array that
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http://www.proteomesci.com/content/10/1/71detects 174 cytokines in one experiment (RayBio Human
Cytokine Antibody Array G series 2000; Raybiotech,
Norcross GA, USA; http://www.raybiotech.com/G_Series.
asp; July 2012). The array consisted of three glass slides
(array 6, 7, and 8) that were pretreated according to the
manufacturer's instructions and incubated with 2-fold
diluted serum pools for 2 hours. All sample measurements
were performed in duplicate. The array glass slides were
washed, incubated with a biotin-conjugated anti-cytokine
mix for 2 hours, washed again, and developed for 2 hours
with Cy3-conjugated streptavidin. The signals were
scanned with a GenePix 4000B scanner (Axon Instru-
ments, GenePix version 5.0) and analyzed with the Ray-
biotech analysis tool, a data analysis program based on
Microsoft Excel technology specifically designed to
analyze Raybiotech Antibody Array G Series. Signals were
normalized using internal, positive and negative controls
included on the array. All data is MIAME compliant and
raw and normalized cytokine microarray data have been
deposited to the Gene Expression Omnibus (GEO) data-
base, Series GSE32041 (accession numbers GSE32037,
GSE32039, GSE32040 and GSE32041).
Determination of cytokine levels by ELISA and
fluorescence bead-based assays
Serum cytokine and growth factor levels were measured
by ELISA (MCP-4, prolactin, RANTES and sIL-2R) or by
fluorescence bead-based assays (ICAM-1, leptin and
PDGF-BB), respectively. ELISA kits specific for human
MCP-4 (DY327) and prolactin (DY682) were purchased
from R&D Systems (Minneapolis, MN, USA). ELISA kits
specific for human RANTES (BMS287/2INST) and IL-
2RA (BMS212INSTCE) were purchased from eBioscience
(Vienna, Austria). Fluorescence bead-based assays (Flow
Cytomix) for human sICAM-1 (BMS80201FF), Leptin
(BMS82039/2FF) and PDGF-BB (BMS82071FF) were
obtained from Bender Med Systems.
All analyses were performed according to the manu-
facturer guidelines. Serum dilutions were 1:2 for MCP-4,
1:10 for prolactin, 1:15 for RANTES, 1:15 for IL-2RA,
1:1 for ICAM-1, 1:1 for IL-6, 1:1 for leptin and 1:1 for
PDGF-BB. Technical details and performance of the
assays used are shown in Additional file 3.
Statistical analysis and bioinformatics
Micorarray data were statistically analyzed with the
TIGR MeV_4_5 (Multiple Experiment Viewer),) Java tool
for genomic data analysis (http://mev-tm4.sourceforge.
net/; July 2012) [32], using the significance analysis of
micoarrays (SAM) method. Multi-class SAM was used
to identify significant cytokines based on differential
expression between the four groups at a false discovery
rate (FDR, expected proportion of false positives among
rejected hypotheses) of 0%.Statistical analysis for the validation experiments
(means, medians, range, standard deviations, significance
of group differences and linear regression) were evalu-
ated using IBM SPSS software (release 18.0, SPSS Inc.,
USA) or GraphPad Prism 5 (GraphPad, San Diego,
USA). Between-group comparisons were performed
with Kruskal-Wallis test, Dunn’s multiple comparison
post-hoc test, Mann–Whitney U test, Fisher’s exact test,
Chi-square test and multivariate analysis. Correlation of
parameters was analyzed with Spearman’s non-parametric
correlation or linear regression analysis. Statistical signifi-
cance was defined as two-sided p-value < 0.05 and
Bonferroni corrections were applied for multiple compari-
sons when appropriate.
The Database for Annotation, Visualization and Inte-
grated Discovery (DAVID) v6.7 was used for functional
annotation clustering of identified cytokines (http://
david.abcc.ncifcrf.gov/) [33].
Additional files
Additional file 1: Results of cytokine microarray experiment.
Additional file 2: Differential expression of PDGF-BB and prolactin
in patients with PSP/CBS, MSA and controls without anti-
Parkinsonian treatment.
Additional file 3: Technical characteristics of the immunoassays
used for validation.
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